Abstract
Melanoma shows a high possibility of mortality after it metastasizes because of its aggressive nature. Although there are several options for anti-melanoma therapy, this skin malignancy is resistant to some therapies. Chemotherapy, biochemotherapy, immunotherapy, and adoptive cell therapy have failed to exhibit a significant amelioration in overall survival. Nanomedicine provides an opportunity to improve the efficiency of the antimelanoma regimen. Nanoparticles for treating melanoma provide the advantages over conventional therapies such as drug solubility increment, drug stability enhancement, epithelium permeability and bioavailability amelioration, half-life prolonging, tumor targeting, and side effect minimization. Polymeric nanocarriers are the most extensively studied platforms for the treatment of a variety of cancers. The polymers' sophisticated material engineering tailors the controllable physicochemical properties of the nanoparticles for melanoma penetration via passive and active delivery. The present study highlights the recent progress on the development of polymeric nanoparticles for melanoma treatment. We describe the concepts and improvement mechanisms of the nanomedical techniques for melanoma treatment. Passive targeting by modifying the structure and physicochemical characters of polymeric nanocarriers is a strategy for efficient drug delivery to the melanoma and its metastasis. On the other hand, active targeting such as peptide or antibody conjugation is another approach delivering the drugs or genes to the nidus site by the nanocarriers. This review offers an overview of the benefits of polymeric nanosystems for treating melanoma.
Keywords: Nanomedicine, polymeric nanoparticle, melanoma, metastasis, drug targeting, chemotherapy.
Current Pharmaceutical Design
Title:Recent Advances in Polymeric Nanosystems for Treating Cutaneous Melanoma and Its Metastasis
Volume: 23 Issue: 35
Author(s): Yi-Ping Chou, Yin-Ku Lin, Chun-Han Chen and Jia-You Fang*
Affiliation:
- Research Center for Industry of Human Ecology and Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Kweishan, Taoyuan,Taiwan
Keywords: Nanomedicine, polymeric nanoparticle, melanoma, metastasis, drug targeting, chemotherapy.
Abstract: Melanoma shows a high possibility of mortality after it metastasizes because of its aggressive nature. Although there are several options for anti-melanoma therapy, this skin malignancy is resistant to some therapies. Chemotherapy, biochemotherapy, immunotherapy, and adoptive cell therapy have failed to exhibit a significant amelioration in overall survival. Nanomedicine provides an opportunity to improve the efficiency of the antimelanoma regimen. Nanoparticles for treating melanoma provide the advantages over conventional therapies such as drug solubility increment, drug stability enhancement, epithelium permeability and bioavailability amelioration, half-life prolonging, tumor targeting, and side effect minimization. Polymeric nanocarriers are the most extensively studied platforms for the treatment of a variety of cancers. The polymers' sophisticated material engineering tailors the controllable physicochemical properties of the nanoparticles for melanoma penetration via passive and active delivery. The present study highlights the recent progress on the development of polymeric nanoparticles for melanoma treatment. We describe the concepts and improvement mechanisms of the nanomedical techniques for melanoma treatment. Passive targeting by modifying the structure and physicochemical characters of polymeric nanocarriers is a strategy for efficient drug delivery to the melanoma and its metastasis. On the other hand, active targeting such as peptide or antibody conjugation is another approach delivering the drugs or genes to the nidus site by the nanocarriers. This review offers an overview of the benefits of polymeric nanosystems for treating melanoma.
Export Options
About this article
Cite this article as:
Chou Yi-Ping , Lin Yin-Ku , Chen Chun-Han and Fang Jia-You *, Recent Advances in Polymeric Nanosystems for Treating Cutaneous Melanoma and Its Metastasis, Current Pharmaceutical Design 2017; 23 (35) . https://dx.doi.org/10.2174/1381612823666170710121348
DOI https://dx.doi.org/10.2174/1381612823666170710121348 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
β-lactam Structured, 4-(4-(Methylsulfonyl)phenyl)-1-pentyl-3-phenoxyazetidin-2-one: Selectively Targets Cancerous B Lymphocyte Mitochondria
Anti-Cancer Agents in Medicinal Chemistry Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System
Current Psychiatry Reviews Preparation and Quality Control of <sup>111</sup>In-Plerixafor for Chemokine Receptor CXCR4
Recent Patents and Topics on Imaging (Discontinued) Viral and Non-Viral Approaches for Transient Delivery of mRNA and Proteins
Current Gene Therapy MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Hybrid Imidazole-Pyridine Derivatives: An Approach to Novel Anticancer DNA Intercalators
Current Medicinal Chemistry Editorial (Thematic Issue: Personalized Cancer Treatment)
Current Molecular Pharmacology Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?
Current Pharmaceutical Design The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Beta-adrenergic Signaling in the Development and Progression of Pulmonary and Pancreatic Adenocarcinoma
Current Cancer Therapy Reviews An overview of ABC and SLC Drug Transporter Gene Regulation
Current Drug Metabolism The Use of Specific Monoclonal Antibodies to Target Immunogenic Tumor Membrane Proteins in Patients with Recurrent Pancreatic and Colon Cancer
Current Drug Delivery Activation of Large Form Galanin-LI by Extracellular Processing in Small Cell Lung Carcinoma Tissue
Protein & Peptide Letters 1,5-Dioxaspiro[2.4]heptanes
Current Chemical Biology Combating Mosquito-Borne Lymphatic Filariasis with Genomics Technologies: Enabling Novel Drug Discovery for Neglected Tropical Diseases
Current Pharmacogenomics and Personalized Medicine Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry Isolation and Boactivities of Furfuran Type Lignan Compounds from Edible Plants
Recent Patents on Food, Nutrition & Agriculture The Small Heat Shock Protein HspB8: Role in Nervous System Physiology and Pathology
CNS & Neurological Disorders - Drug Targets A Single Center Phase II Study of Continuous Infusion of Low-dose 5- fluorouracil for Heavily Pretreated Patients With Metastatic Colorectal Cancer
Clinical Cancer Drugs Nucleic-Acid Delivery Using Lipid Nanocapsules
Current Pharmaceutical Biotechnology